Literature DB >> 14576123

Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole.

Wei Liu1, Michail S Lionakis, Russell E Lewis, Nathan Wiederhold, Gregory S May, Dimitrios P Kontoyiannis.   

Abstract

Fluconazole (FLC), a triazole with limited activity against Aspergillus species, is frequently used as prophylaxis in leukemia patients and bone marrow transplant recipients. Prior FLC use has been associated with an increasing incidence of invasive aspergillosis in these patients. We hypothesized that prior exposure of Aspergillus fumigatus to FLC could result in altered in vitro susceptibility of this fungus to other, more active triazoles. Thus, we performed serial passages of conidia of 10 clinical isolates of A. fumigatus (all itraconazole [ITC] susceptible) on FLC-containing yeast agar glucose plates. The MICs and minimal fungicidal concentrations (MFCs) of amphotericin B, FLC, ITC, and voriconazole (VRC) for A. fumigatus conidia were measured following four passages on FLC-containing medium according to the National Committee for Clinical Laboratory Standards microdilution method. Serial passages on FLC-containing plates resulted in a fourfold increase in the MFCs (but not the MICs) of ITC for nine isolates. The attenuated ITC fungicidal activity against A. fumigatus following FLC preexposure was medium independent and was also observed against FLC-preexposed A. fumigatus hyphae with the viability staining FUN-1 dye. Moreover, FLC preexposure of A. fumigatus conidia resulted in an analogous increase in the MFCs (but not the MICs) of VRC. Our findings suggest that preexposure of A. fumigatus to FLC attenuates the in vitro fungicidal activity of subsequent ITC use against it. This phenotypic adaptation is not captured by a routine MIC determination but requires MFC measurement. The in vivo significance of this in vitro phenomenon requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576123      PMCID: PMC253799          DOI: 10.1128/AAC.47.11.3592-3597.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Glycopeptide antibiotic resistance.

Authors:  Jeff Pootoolal; John Neu; Gerard D Wright
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 2.  Invasive aspergillosis in 2002: an update.

Authors:  D P Kontoyiannis; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-22       Impact factor: 3.267

Review 3.  Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices.

Authors:  N Singh
Journal:  Clin Infect Dis       Date:  2001-10-12       Impact factor: 9.079

4.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; A Fothergill; J Peter; M G Rinaldi; T J Walsh
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.

Authors:  Eric J Bow; Michel Laverdière; Nathalie Lussier; Coleman Rotstein; Mary S Cheang; Stratis Ioannou
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

View more
  4 in total

1.  Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro.

Authors:  Weixia Liu; Lijuan Li; Yi Sun; Wei Chen; Zhe Wan; Ruoyu Li; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

2.  Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.

Authors:  Anne-Pauline Bellanger; Nathaniel D Albert; Russell E Lewis; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae.

Authors:  Cristina Gil-Lamaignere; Stefanie Salvenmoser; Regina Hess; Frank-Michael C Müller
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015.

Authors:  Sang Taek Heo; Alexander M Tatara; Cristina Jiménez-Ortigosa; Ying Jiang; Russell E Lewis; Jeffrey Tarrand; Frank Tverdek; Nathaniel D Albert; Paul E Verweij; Jacques F Meis; Antonios G Mikos; David S Perlin; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.